Everything below concerns preclinical research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Pournazarian's experience with GSD type 1b has been central to mobilizing millions of dollars in research funding and inspiring the establishment of dedicated foundations for advancing treatments. His family continues to be active in advocacy efforts, working with organizations such as CureGSD1b to support research and provide resources for affected families. (See inborn errors of carbohydrate metabolism for a full list of inherited diseases that affect glycogen synthesis, glycogen breakdown, or glucose breakdown.)
Radon is a member of the zero-valence elements that are called noble gases, and is chemically not very reactive. The inert pair effect stabilizes the 6s shell, making it unavailable for bonding—a consequence only understood within relativistic quantum chemistry. The 3.8-day half-life of 222Rn makes it useful in physical sciences as a natural tracer. Because radon is a gas at standard conditions, unlike its decay-chain parents, it can readily be extracted from them for research. It is inert to most common chemical reactions, such as combustion, because the outer valence shell contains eight electrons. This produces a stable, minimum energy configuration in which the outer electrons are tightly bound. Its first ionization energy—the minimum energy required to extract one electron from it—is 1037 kJ/mol. In accordance with periodic trends, radon has a lower electronegativity than the element one period before it, xenon, and is therefore more reactive. Early studies concluded that the stability of radon hydrate should be of the same order as that of the hydrates of chlorine (Cl2) or sulfur dioxide (SO2), and significantly higher than the stability of the hydrate of hydrogen sulfide (H2S). Because of its cost and radioactivity, experimental chemical research is seldom performed with radon, and as a result there are very few reported compounds of radon, all either fluorides or oxides. Radon can be oxidized by powerful oxidizing agents such as fluorine, thus forming radon difluoride (RnF2).
== Clinical significance == The clinical significance in humans is becoming clear. From parallels in the mouse studies, there may be diseases where its function could be relevant. In a mouse model of thalassemia, its expression is increased, resulting in iron overload, which is also a feature of the human disease. A role in the recovery from the anemia of inflammation in mice has been shown and involvement in inherited anemias with ineffective erythropoiesis, anemia of chronic kidney diseases and iron-refractory iron-deficiency anemia has been suggested. Erythroferrone levels in blood have been shown by immunoassay to be higher after blood loss or erythropoetin administration. Patients with beta-thalassemia have very high levels, and these decrease after blood transfusion.
Sources: en.wikipedia.org
=== Modes of action === The cytotoxic activity of docetaxel is exerted by promoting and stabilising microtubule assembly, while preventing physiological microtubule depolymerisation/disassembly in the absence of GTP. This leads to a significant decrease in free tubulin, needed for microtubule formation and results in inhibition of mitotic cell division between metaphase and anaphase, preventing further cancer cell progeny. Because microtubules do not disassemble in the presence of docetaxel, they accumulate inside the cell and cause initiation of apoptosis. Apoptosis is also encouraged by the blocking of apoptosis-blocking bcl-2 oncoprotein. Both in vitro and in vivo analysis show the anti-neoplastic activity of docetaxel to be effective against a wide range of known cancer cells, cooperate with other anti-neoplastic agents activity, and have greater cytotoxicity than paclitaxel, possibly due to its more rapid intracellular uptake. The main mode of therapeutic action of docetaxel is the suppression of microtubule dynamic assembly and disassembly, rather than microtubule bundling leading to apoptosis, or the blocking of bcl-2.
==== Obesity and osteoarthritis ==== Osteoarthritis and obesity are closely linked. Obesity is one of the most important preventable factors for the development of osteoarthritis. Originally, the relationship between osteoarthritis and obesity was considered to be exclusively biomechanically based, according to which the excess weight caused the joint to become worn down more quickly. However, today we recognise that there is also a metabolic component which explains why obesity is a risk factor for osteoarthritis, not only for weight-bearing joints (for example, the knees), but also for joints that do not bear weight (for example, the hands). Consequently, it has been shown that decreasing body fat lessens osteoarthritis to a greater extent than weight loss per se. This metabolic component related with the release of systemic factors, of a pro-inflammatory nature, by the adipose tissues, which frequently are critically associated with the development of osteoarthritis. Thus, the deregulated production of adipokines and inflammatory mediators, hyperlipidaemia, and the increase of systemic oxidative stress are conditions frequently associated with obesity, which can favour joint degeneration. Furthermore, many regulation factors have been implicated in the development, maintenance, and function, both of adipose tissues, as well as of the cartilage and other joint tissues. Alterations in these factors can be the additional link between obesity and osteoarthritis.
depending on the diameter and the type of pipe wall. Weisbach's work was published in the United States in 1848 and soon became well known there. In contrast, it did not initially gain much traction in France, where Prony equation, which had a polynomial form in terms of velocity (often approximated by the square of the velocity), continued to be used. Beyond the historical developments, Weisbach's formula had the objective merit of adhering to dimensional analysis, resulting in a dimensionless friction factor f. The complexity of f, dependent on the mechanics of the boundary layer and the flow regime (laminar, transitional, or turbulent), tended to obscure its dependence on the quantities in Weisbach's formula, leading many researchers to derive irrational and dimensionally inconsistent empirical formulas. It was understood not long after Weisbach's work that the friction factor f depended on the flow regime and was independent of the Reynolds number (and thus the velocity) only in the case of rough pipes in a fully turbulent flow regime (Prandtl-von Kármán equation).
Sources: en.wikipedia.org
==== EPS in building construction ==== Sheets of EPS are commonly packaged as rigid panels (common in Europe is a size of 100 cm x 50 cm, usually depending on an intended type of connection and glue techniques, it is, in fact, 99.5 cm x 49.5 cm or 98 cm x 48 cm; less common is 120 x 60 cm; size 4 by 8 ft (1.2 by 2.4 m) or 2 by 8 ft (0.61 by 2.44 m) in the United States). Common thicknesses are from 10 mm to 500 mm. Many customizations, additives, and thin additional external layers on one or both sides are often added to help with various properties. An example of this is lamination with cement board to form a structural insulated panel. Thermal conductivity is measured according to EN 12667. Typical values range from 0.032 to 0.038 W/(m⋅K) depending on the density of the EPS board. The value of 0.038 W/(m⋅K) was obtained at 15 kg/m3 while the value of 0.032 W/(m⋅K) was obtained at 40 kg/m3 according to the datasheet of K-710 from StyroChem Finland. Adding fillers (graphites, aluminum, or carbons) has allowed the thermal conductivity of EPS to reach around 0.030–0.034 W/(m⋅K) (as low as 0.029 W/(m⋅K)) and as such has a grey/black color which distinguishes it from standard EPS. Several EPS producers have produced a variety of these increased thermal resistance EPS usage for this product in the UK and EU. Water vapor diffusion resistance (μ) of EPS is around 30–70. ICC-ES (International Code Council Evaluation Service) requires EPS boards used in building construction meet ASTM C578 requirements.
=== MDP-apatite or dentin interactions === The adhesive interaction of MDP with synthetic hydroxyapatite was observed using x-ray photoelectron spectroscopy and atomic absorption spectrophotometry. MDP readily adhered to hydroxyapatite and this bond appeared very stable, as confirmed by the low dissolution rate of its calcium salt in water. MDP, which effectively interacts chemically with hydroxyapatite and the calcium salt of which is hardly soluble, showed no signs of degradation in bond strength. Micro-tensile bond strength (μTBS) to dentin of a self-etch adhesive that contains MDP were measured up to 100,000 thermocycles. The μTBS of the MDP-based adhesive to dentin after 100,000 thermocycles was not significantly different from that of the control. Experimental primers, which were prepared by three different purity grade MDP monomers, were tested. Impurities and the presence of MDP dimer affected not only hybridization, but also reduced the formation of MDP_Ca salts and nano-layering. MDP in a high purity grade is essential to achieve durable bonding.
Symptoms can vary from aches or pains and local joint stiffness, to a burning that surrounds the whole joint around the inflamed tendon. In some cases, swelling occurs along with heat and redness, and there may be visible knots surrounding the joint. With this condition, the pain is usually worse during and after activity, and the tendon and joint area can become stiff the following day as muscles tighten from the movement of the tendon. Many patients report stressful situations in their life in correlation with the beginnings of pain which may contribute to the symptoms.
== History == The history of today's Gelita AG in Eberbach dates back to 1875, when the production of gelatin was started in Schweinfurt. Gelita was preceded by the founding of the "Gebrüder Köpff Company", Heinrich Koepff's small tannery, in 1883. Shaken by the economic crisis of the time, Heinrich saw a way out of his misery in gelatin production. The raw material for this could be purchased cheaply, as it was produced in the large tanneries as residual material. With around 60 employees, the factory was already producing photographic gelatin in 1884, which was an important material for the rapidly emerging photography in the 19th century. In 1887, the Koepff brothers acquired the competing company A. & C. Wolff in Heilbronn. Both locations had 320 employees who produced 400 tonnes of gelatin per year. In 1901, a major fire destroyed large parts of the factory. The brothers quarreled over reconstruction. Heinrich went to Heilbronn and Paul Koepff continued to run the rebuilt plant alone under the name Göppinger Gelatin Factory Paul Koepff. In 1911, he sold the factory to DGF AG, which already operated gelatin factories in Schweinfurt and Höchst. Paul Koepff was henceforth on the board of directors and continued to manage his former company as director. In 1929, Paul Koepff jr. took over the management of the Göppingen plant from his father, who died in 1953. The Gelita Brand was introduced in 1934. In 1937, the DGF was accused of violating foreign trade regulations and leading employees were arrested.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.